Azra Kurbasic
Overview
Explore the profile of Azra Kurbasic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1097
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham S, Clarke S, Wu K, Kanoni S, Zajac G, Ramdas S, et al.
Nature
. 2023 May;
618(7965):E19-E20.
PMID: 37237109
No abstract available.
2.
Paller A, Flohr C, Cork M, Bewley A, Blauvelt A, Hong H, et al.
JAMA Dermatol
. 2023 Apr;
159(6):596-605.
PMID: 37074705
Importance: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. Objective: To evaluate the efficacy and safety of interleukin-13-targeted treatment with tralokinumab monotherapy...
3.
Kanoni S, Graham S, Wang Y, Surakka I, Ramdas S, Zhu X, et al.
Genome Biol
. 2022 Dec;
23(1):268.
PMID: 36575460
Background: Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of...
4.
Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, et al.
Nature
. 2022 Oct;
610(7933):704-712.
PMID: 36224396
Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40-50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes. Here, using...
5.
Blauvelt A, Gooderham M, Bhatia N, Langley R, Schneider S, Zoidis J, et al.
Dermatol Ther (Heidelb)
. 2022 Sep;
12(11):2499-2516.
PMID: 36152216
Introduction: In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to-severe atopic dermatitis (AD), tralokinumab significantly improved signs and symptoms...
6.
Ramdas S, Judd J, Graham S, Kanoni S, Wang Y, Surakka I, et al.
Am J Hum Genet
. 2022 Aug;
109(8):1366-1387.
PMID: 35931049
A major challenge of genome-wide association studies (GWASs) is to translate phenotypic associations into biological insights. Here, we integrate a large GWAS on blood lipids involving 1.6 million individuals from...
7.
Simpson E, Wollenberg A, Soong W, Steffensen L, Kurbasic A, Schneider S, et al.
Ann Allergy Asthma Immunol
. 2022 Jul;
129(5):592-604.e5.
PMID: 35843520
Background: Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis and additional...
8.
Poveda A, Pomares-Millan H, Chen Y, Kurbasic A, Patel C, Renstrom F, et al.
Sci Rep
. 2022 Mar;
12(1):4088.
PMID: 35260745
The present study assessed the temporal associations of ~ 300 lifestyle exposures with nine cardiometabolic traits to identify exposures/exposure groups that might inform lifestyle interventions for the reduction of cardiometabolic...
9.
Wesolowska-Andersen A, Brorsson C, Bizzotto R, Mari A, Tura A, Koivula R, et al.
Cell Rep Med
. 2022 Feb;
3(1):100477.
PMID: 35106505
The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility...
10.
Graham S, Clarke S, Wu K, Kanoni S, Zajac G, Ramdas S, et al.
Nature
. 2021 Dec;
600(7890):675-679.
PMID: 34887591
Increased blood lipid levels are heritable risk factors of cardiovascular disease with varied prevalence worldwide owing to different dietary patterns and medication use. Despite advances in prevention and treatment, in...